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Abstract
Background
Chronic Lung Allograft Dysfunction (CLAD) is the main limitation to long-term survival after
lung transplantation. Although CLAD is usually not responsive to treatment, earlier identifi-
cation may improve treatment prospects.
Methods
In a nested case control study, 1-year post transplant surveillance bronchoalveolar lavage
(BAL) fluid samples were obtained from incipient CLAD (n = 9) and CLAD free (n = 8) lung
transplant recipients. Incipient CLAD cases were diagnosed with CLAD within 2 years, while
controls were free from CLAD for at least 4 years following bronchoscopy. Transcription pro-
files in the BAL cell pellets were assayed with the HG-U133 Plus 2.0 microarray (Affymetrix).
Differential gene expression analysis, based on an absolute fold change (incipient CLAD vs
no CLAD) >2.0 and an unadjusted p-value0.05, generated a candidate list containing 55
differentially expressed probe sets (51 up-regulated, 4 down-regulated).
Results
The cell pellets in incipient CLAD cases were skewed toward immune response pathways,
dominated by genes related to recruitment, retention, activation and proliferation of cytotoxic
lymphocytes (CD8+ T-cells and natural killer cells). Both hierarchical clustering and a super-
vised machine learning tool were able to correctly categorize most samples (82.3% and
94.1% respectively) into incipient CLAD and CLAD-free categories.
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Conclusions
These findings suggest that a pathobiology, similar to AR, precedes a clinical diagnosis of
CLAD. A larger prospective investigation of the BAL cell pellet transcriptome as a biomarker
for CLAD risk stratification is warranted.
Introduction
Lung transplant is a therapeutic option for end-stage pulmonary disorders, but long-term sur-
vival is dependent upon remaining free from chronic lung allograft dysfunction (CLAD),
which affects greater than 50% of recipients within 5 years. CLAD is characterized by the inex-
orable loss of lung function, and the typical survival following CLAD diagnosis is less than 3
years [1]. The diagnosis of CLAD relies on a 20% or greater decline in the forced expiratory
volume in 1 second (FEV1), sustained over at least 3 weeks, from the post-transplant baseline.
Although several phenotypes of CLAD have been described; the most common and best
described exhibits physiologic airflow obstruction and is termed bronchiolitis obliterans syn-
drome (BOS). Unfortunately, regardless of the CLAD phenotype, by the time a clinical diagno-
sis is made, treatment is usually ineffective [2]. Earlier detection may improve treatment
prospects, but there is currently no reliable method to detect CLAD before it is physiologically
evident.
Many lung transplant centers utilize surveillance bronchoscopy with bronchoalveolar
lavage (BAL) and transbronchial biopsy to monitor for asymptomatic acute rejection (AR)
and infection. However, transbronchial biopsy is not a reliable method to diagnose CLAD due
to the very small tissue size obtained and the patchy nature of the disease. However, BAL offers
an alternative and larger window for observing lung biology as it samples a much larger area of
the allograft. While the dilution factor may affect protein concentrations, this is not an issue
when studying the cellular component returned in the BAL fluid. Therefore, transcription pro-
filing of the BAL cell pellet (CP) may be a useful tool to monitor the immune response in the
lung allograft and to provide mechanistic information about CLAD pathogenesis. Given that
the onset of CLAD pathogenesis must precede our ability to make a clinical diagnosis, we
hypothesized that transcription profiles from the BAL CP would be associated with incipient
CLAD and be informative about the pathobiology responsible for CLAD development.
This study was conceptualized by Clinical Trials in Organ Transplantation (CTOT)-20
investigators in order to compile preliminary data for a Clinical Trials in Organ Transplanta-
tion (CTOT) ancillary studies proposal. CTOT-20 is a prospective multicenter observational
cohort study to define the risk factors, mechanisms, and manifestations of CLAD phenotypes
sponsored by the National Institute of Allergy and Infectious Diseases (NIAID). Samples
were collected prior to initiation of CTOT-20 but consistent with the protocols and standards
specified by CTOT. The protocol was approved by the UCLA Institutional Review Board
(#10–001492) and all subjects provided written informed consent to participate in the study.
Patients and Methods
Identification of study patients
Lung transplant recipients at UCLA undergo surveillance bronchoscopy at 1, 3, 6, and 12
months post-transplant, and when clinically indicated. Since 2001, a subset of recipients was
enrolled in an observational registry study that included the collection of BAL fluid for
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research purposes at the time of standard of care bronchoscopies. The registry includes stan-
dardized medical record abstraction including demographic, transplantation, and outcome
related variables. For this nested case control study, eligible subjects were those with a 1 year
surveillance bronchoscopy that was negative for rejection and infection, with the correspond-
ing research BAL sample available in our biorepository. Subjects meeting these criteria were
then screened for incipient CLAD and CLAD free phenotypes. Incipient CLAD was defined as
a clinical diagnosis of CLAD within 730 days following the bronchoscopy. CLAD was diag-
nosed according to ISHLT criteria, defined as a sustained drop in FEV1 by at least 20% from
the average of the 2 best post-transplant FEV1 measurements [3]. CLAD free control recipients
remained without CLAD for at least 4 years following the 12 month bronchoscopy.
Our repository included 70 BAL samples from eligible subjects, 23 which met criteria for
incipient CLAD cases and 23 which met criteria for CLAD free controls (Fig 1). The remaining
subjects were excluded for either delayed CLAD (n = 16) or insufficient follow-up time to
establish freedom from CLAD for at least 4 years post-BAL (n = 8).
Bronchoalveolar lavage fluid sample collection and processing
The BAL procedure was done according to a standardized protocol using three 60-ml aliquots
of isotonic saline instilled into a subsegmental bronchus of either the right middle lobe or left
lingula. Retrieved BAL fluid was pooled and then split into a 15 ml clinical specimen and a
research specimen with the remaining volume. The freshly acquired research samples were
immediately placed on ice for transport to the lab where they were processed within 6 hours of
collection. Briefly, the BAL fluid was filtered through sterile gauze, the cells were counted, and
cytospin preparations were made for differential cell counts. The remaining cells were sepa-
rated from fluid by centrifugation. Cells were washed twice with phosphate-buffered saline
and lysed in TRIzol (Invitrogen, Carlsbad, CA).
RNA extraction and microarray analysis
Total RNA was isolated using TRIzol/chloroform extraction, re-suspended in RNase-free
water and purified using the miRNeasy Mini kit (Qiagen Inc, Valencia, CA). RNA was dis-
carded if the 260/280 ratio was not between 1.8 and 2.1, or if RNA showed evidence of
degradation (RNA integrity number less than 7.0) when assessed with the Agilent 2100 BioA-
nalyzer (Agilent Technologies, Palo Alto, CA). In total, we were left with 9 incipient CLAD
samples and 8 CLAD free samples of sufficient quality to move forward for microarray
analysis.
The poly(A) RNA was converted to cDNA, which was used for in vitro transcription of
biotin-labeled cRNA. Hybridization with the biotin labeled RNA, staining, and scanning of the
chips followed the procedure outlined in the Affymetrix technical manual. All analyses used
the Affymetrix Human U133 plus 2.0 array, which contains approximately 48,000 probe sets
designed from GenBank, dbEST, and RefSeq sequences clustered based on build 133 of the
UniGene database and an additional 6500 transcripts identified from Unigene build 159. Back-
ground correction utilized the Robust Multi-Array Average (RMA) method [4, 5]. Data were
normalized with quantile normalization and Tukey’s Median Polish Approach was used to
summarize probe intensities [6]. We focused on probe sets meeting the following criteria: 1)
More than 50% arrays have expression index (log2 scale) of at least 3. This step eliminates
probes with low expression index. 2) Coefficient of variation is greater than 0.2 across all
arrays. This step excludes probes with low variability. Using these criteria, 23,271 out of 54,675
probes remained after non-specific filtering.
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Statistical methods
Subject’s clinical characteristics were displayed as a column percentage, mean ± SD, or median
with interquartile range as described. Categorical data were compared using Fisher’s exact test.
Continuous data were compared using the Mann-Whitney test.
Fig 1. Sample selection flow chart. LTR, lung transplant recipient. BAL, bronchoalveolar lavage. CLAD, chronic lung allograft dysfunction. RIN, RNA
integrity number.
doi:10.1371/journal.pone.0169894.g001
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Bioconductor package LIMMA (linear models for microarray data) [7] was used for differ-
ential gene expression analysis. Due to the relatively small number of arrays, empirical Bayes-
ian method is adopted to provide stable testing results. A candidate list of differential
expressed probe sets were identified using a volcano plot that showed > 2 fold or< -2 fold dif-
ferential expression and were significant by LIMMA’s moderated t-test (p< 0.05) between
incipient CLAD and CLAD free. For functional annotation and pathway enrichment analysis,
the candidate probes were analyzed in Database for Annotation, Visualization and Integrated
Discovery (DAVID) [8, 9] and processes and pathways were selected based on Benjamini and
Hochberg [10] adjusted p-values smaller than 0.05. Principal component analysis (PCA) [11]
was used to visualize the separation of the two groups based on expression profiles of the
selected candidate probes. Further unsupervised hierarchical clustering of differentially
expressed probes was done by applying the Ward’s minimum variance criterion linkage
method [12] with Euclidean distance and presented in a heat map.
A supervised machine learning tool, support vector machine (SVM) [13], was used for clas-
sification of patient samples into incipient CLAD and CLAD-free categories. Essentially, a
binary support vector machine is an algorithm that looks for the optimal hyperplane of sepa-
rating the two classes by maximizing the margin between the closest points of the two classes.
The points on the boundaries are called support vectors, while our optimal separating
hyperplane is located in the middle of the margin. Literature suggests SVM classifiers have
superior and robust performance in identifying predictive biomarkers in the setting of high-
dimensional microarray gene expression data [14–18]. To overcome overfitting due to small
number of arrays and large number of features, we also performed recursive feature elimina-
tion (SVM-RFE) algorithm [19] on the SVM to remove features with smallest ranking crite-
rion, which corresponds to components of the SVM weight vector that are smallest in absolute
value. Performance of our SVM is assessed by leave-one-out cross validation. All the statistical
analyses were conducted using Bioconductor suite of packages [20] in the R statistical software
environment version 3.2.3 [21].
The data discussed in this publication are available in the ArrayExpress database (http://
www.ebi.ac.uk/arrayexpress) under accession number E-MTAB-5029 [22].
Results
Patient characteristics
Our repository included 23 samples which met criteria for incipient CLAD cases and 23 which
met criteria for CLAD free controls (Fig 1). A priori, we specified we would include only high
integrity RNA samples (RIN6.5), thus we had to exclude 29 additional samples with RIN
<6.5, leaving seventeen samples from unique subjects, including 9 samples with incipient
CLAD and 8 samples classified as CLAD free. Subject characteristics of included and excluded
subjects, for cases and controls, were similar between groups as shown in Table 1. All 9
included cases of incipient CLAD were consistent with the BOS phenotype, based upon stable
FVC and lack of fibrotic changes on CT, as compared to 3 excluded subjects with restrictive
CLAD. Kaplan Meier 1-, 3-, and 5-year survival estimates following a diagnosis of CLAD were
56%, 44%, and 22% and 57%, 36%, and 14% for included and excluded CLAD cases respec-
tively (log-rank P = 0.72).
Among included samples, most characteristics of cases and controls were similar. While the
FEV1 percent predicted were identical in CLAD free controls and incipient CLAD cases, the
FEV1 percent of baseline was lower in the incipient CLAD group (P = 0.01), where 5 subjects
met criteria for BOS0p as compared to no patient in the CLAD free cohort. At the time of sam-
ple collection, all includes cases and controls were on maintenance immune suppression
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consisting of tacrolimus, MMF, and low dose prednisone, except for 1 patient in each group
where sirolimus had been exchanged for MMF. No patient was being treated with Azithromy-
cin at the time of sample collection. In the CLAD free controls, the median time from sample
to last follow-up was 78.4 (IQR 55.2–83.5) months. In the incipient CLAD cases, the time from
sample to CLAD diagnosis was usually less than 1 year, with a median of 7.3 (IQR 3.3–12.9)
months.
BAL cell counts and differential
We did not make any effort to fractionate cells before RNA isolation. Thus, it is possible that
differences in gene expression could reflect differences in the leukocyte cellular proportions
within the BAL CPs. To assess this, we compared the BAL total cell counts and differential
counts between samples from CLAD free and incipient CLAD cases. The median total cell
counts per ml of BAL fluid were similar in the CLAD free and incipient CLAD groups (1.1 vs.
1.4 x 105, P = 0.62). Macrophages made the majority of cells for each sample. Neither neutro-
phil nor lymphocyte percentages differed significantly between CLAD free and incipient
CLAD groups (Fig 2).
Differential gene expression analyses
Based upon an absolute fold change>2.0 and unadjusted p-value<0.05, differential gene
expression analysis identified 55 differentially expressed probe sets, 51 over- and 4 under-
expressed probes with incipient CLAD as compared to the CLAD free group (Fig 3). The 55
differentially expressed probes map to 40 unique candidate genes, listed in Table 2.
Table 1. Clinical characteristics of the CLAD Free and Incipient CLAD cohorts.
CLAD Free Included
(n = 8)
CLAD Free Excluded
(n = 15)
Incipient CLAD Included
(n = 9)
Incipient CLAD Excluded
(n = 14)
P-value
Sex (%) 0.52
Male 3 (38) 10 (67) 6 (67) 9 (64)
Female 5 (62) 5 (33) 3 (33) 5 (36)
Age at transplant, mean ± SD 57.3 ± 9.7 54.2 ± 9.9 57.9 ± 6.6 60.7 ± 8.3 0.28
Pre-transplant disease (%) 0.95
COPD 3 (38) 5 (33) 2 (22) 5 (36)
Restrictive lung disease 4 (50) 8 (53) 6 (67) 6 (43)
Other 1 (12) 2 (13) 1 (11) 3 (21)
Type of Transplant (%) 0.08
Bilateral 6 (75) 11 (73) 9 (100) 7 (50)
Single 2 (25) 4 (37) 0 (0) 7 (50)
FEV1% predicted, median
(IQR)†
74 (68–98) 71 (51–93) 74 (72–91) 67 (57–89) 0.54
FEV1% of baseline, median
(IQR)†
98 (96–100) 96 (93–100) 87 (84–95) 91 (86–96) 0.006a
Months to Sample, median
(IQR)
12.4 (12.2–12.5) 12.6 (11.7–14.3) 13.6 (12.3–18.8) 12.8 (12.4–15.2) 0.24
RNA Integrity Number,
median (IQR)
7.8 (7.1–8.0) 4.3 (2.7–5.5) 8.1 (7.6–9.0) 4.9 (3.3–5.2) <0.0001b
†Characteristics are at the time of sample acquisition.
aComparison of CLAD Free Included vs. Incipient CLAD Included by Mann Whitney P = 0.01.
bComparison of CLAD Free Included vs. Incipient CLAD Included by Mann Whitney P = 0.14.
doi:10.1371/journal.pone.0169894.t001
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Functional annotation and pathway enrichment analyses
The list of 40 candidate genes was submitted for functional annotation and pathway analysis
using DAVID Bioinformatics Resources [9, 23]. Comparison of the biological process category
of gene ontology (GO) classification indicated that the predominant processes were related to
activation or differentiation of immune cells or to an immune response in general (Table 3).
Similarly, pathways significantly enriched in this gene list included the Reactome pathway
“signaling in immune system” and Kyoto Encyclopedia of Genes and Genomes (KEGG) path-
ways “natural killer cell mediated cytotoxicity” and “graft-versus-host disease” (Table 4).
Cluster analysis of significant genes and relationship to incipient CLAD
Principle Component Analysis based on the 40 unique genes differentially expressed demon-
strated modest separation of incipient CLAD and CLAD free samples (Fig 4). To further evalu-
ate the potential for our gene list to discriminate incipient CLAD patients from no CLAD
patients, we performed unsupervised hierarchical clustering based on the Euclidean distance
dissimilarity measure, and Ward’s minimum variance criterion linkage method. Using these
methods, we identified 2 major clusters of patient samples. In the first cluster, 6 of 7 samples
were from no CLAD patients. In the second cluster, 8 of 10 samples were from incipient
CLAD patients (Fig 5).
Classifier training, feature selection and cross validation
We developed a support vector machine (SVM) classifier to separate patient samples into
incipient CLAD and CLAD-free categories. The training data set consists of 40 features from
Fig 2. BAL cell differential. (A) Percentage of neutrophils among the BAL cells by sample. (B) Percent neutrophils analysis
(Mann Whitney test) by CLAD Free versus Incipient CLAD group. (C) Percentage of lymphocytes among the BAL cells by sample.
(D) Percent lymphocytes analysis (Mann Whitney test) by CLAD Free versus Incipient CLAD group.
doi:10.1371/journal.pone.0169894.g002
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all 17 arrays (9 incipient CLAD, 8 CLAD-free). Our SVM is trained by both linear and non-
linear kernel functions with a varying set of kernel parameters. Based on 40 features, a SVM
with linear kernel and cost function = 1 is constructed. There are 7 support vectors (i.e. 7
arrays on the boundaries). The leave-one-out cross validation error is 11.7%. This SVM cor-
rectly classifies 14 out of the 17 samples with accuracy of 82.3%. After recursive feature
Fig 3. Volcano plot visualization of differential gene expression. DAE generated a candidate list of 55 probe sets, 51 over- and 4 under-expressed
in the incipient CLAD as compared to the CLAD free group.
doi:10.1371/journal.pone.0169894.g003
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Table 2. Unique genes differentially expressed during Incipient CLAD vs. No CLAD.
Gene Name Gene Symbol (GenBank Acc) FC P-value
Down-regulated genes
- - - (BG389789) -4.51 0.017
egf-like module containing, mucin-like, hormone receptor-like 1 EMR1 -2.53 0.015
- - - (H78083) -2.24 0.017
fibronectin type III domain containing 3B FNDC3B -2.07 0.037
Up-regulated genes
chemokine (C-X-C motif) ligand 13 CXCL13 5.48 0.009
hemoglobin, alpha 1 /// hemoglobin, alpha 2 HBA1 /// HBA2 5.31 0.014
hemoglobin, beta HBB 4.41 0.021
granzyme A (granzyme 1, cytotoxic T-lymphocyte-associated serine esterase 3) GZMA 3.33 0.011
granzyme H (cathepsin G-like 2, protein h-CCPX) GZMH 2.96 0.007
T cell receptor beta constant 1 TRBC1 2.86 0.029
B-cell CLL/lymphoma 11B (zinc finger protein) BCL11B 2.79 0.017
chemokine (C-C motif) ligand 5 CCL5 2.67 0.046
CD8a molecule CD8A 2.58 0.017
perforin 1 (pore forming protein) PRF1 2.55 0.014
regulator of G-protein signaling 1 RGS1 2.48 0.021
LCK proto-oncogene, Src family tyrosine kinase LCK 2.47 0.032
granulysin GNLY 2.45 0.041
NLR family, CARD domain containing 3 NLRC3 2.42 0.029
- - - (AI949912) 2.37 0.004
HOP homeobox HOPX 2.35 0.016
ADP-ribosylation factor-like 4C ARL4C 2.33 0.034
killer cell lectin-like receptor subfamily C, member 1, member 2 KLRC1 /// KLRC2 2.32 0.038
microRNA 6883 /// period circadian clock 1 PER1 2.31 0.001
killer cell lectin-like receptor subfamily K, member 1 KLRK1 2.31 0.031
eomesodermin EOMES 2.30 0.010
natural killer cell granule protein 7 NKG7 2.29 0.036
- - - (AI475680) 2.25 0.017
tripartite motif containing 58 TRIM58 2.24 0.033
annexin A1 ANXA1 2.23 0.036
B-cell translocation gene 1, anti-proliferative BTG1 2.19 0.011
killer cell lectin-like receptor subfamily D, member 1 KLRD1 2.17 0.011
plastin 3 PLS3 2.14 0.029
- - - RP11-489E7.4 2.13 0.016
ATPase, aminophospholipid transporter, class I, type 8B, member 2 ATP8B2 2.11 0.049
cytotoxic T-lymphocyte-associated protein 4 CTLA4 2.08 0.047
synuclein, alpha (non A4 component of amyloid precursor) SNCA 2.05 0.014
chloride intracellular channel 3 CLIC3 2.05 0.020
killer cell lectin-like receptor subfamily B, member 1 KLRB1 2.04 0.035
transmembrane protein 200A TMEM200A 2.04 0.039
sterile alpha motif domain containing 3 SAMD3 2.01 0.017
doi:10.1371/journal.pone.0169894.t002
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elimination, a SVM with the top 10 features has a 94.1% accuracy (16 out of 17 correctly identi-
fied) on the training data based on leave-one-out cross validation.
Discussion
This study of the BAL CP transcriptome after lung transplantation is the first to examine gene
expression relative to the future development of CLAD. We make the novel observation that
incipient CLAD, defined as CLAD onset within 2 years of BAL collection, is associated with a
distinct BAL CP gene expression profile. More specifically, the incipient CLAD profile pre-
dominantly exhibits differentially expressed genes related to recruitment, retention, activation
and proliferation of cytotoxic lymphocytes (CD8+ T-cells and natural killer [NK] cells). These
findings validate the utility of the BAL CP transcriptome as a tool for investigating the patho-
genesis of CLAD. Furthermore, we confirm that the onset of pathogenesis precedes our ability
to make the clinical diagnosis of CLAD, and suggests that the BAL CP transcriptome is a useful
biomarker for CLAD development.
While we note a non-significant trend for increased percentage of BAL neutrophils in
incipient CLAD samples, the differentially expressed gene profile was not suggestive of a neu-
trophil mediated process. In contrast, several differentially expressed genes favor recruitment
and retention of mononuclear immune cells in the lung allograft that develops CLAD. For
instance, incipient CLAD is associated with upregulated expression of the CC chemokine,
RANTES/CCL5, a chemoattractant for mononuclear leukocytes [24]. Importantly, we have
previously found CCL5 protein concentrations to be increased in human BALF during both
AR and pulmonary cytomegalovirus (CMV) infection, both putative risk factors for CLAD
Table 3. Gene ontology: biological processes significantly associated with incipient CLAD.
GOTERM Count % Gene Symbols P-Value Adjusted P-Value
leukocyte activation 7 19.4 NLRC3, EOMES, SNCA, BCL11B, CD8A, LCK, KLRK1 1.28E-05 0.008
cell activation 7 19.4 NLRC3, EOMES, SNCA, BCL11B, CD8A, LCK, KLRK1 3.35–05 0.010
lymphocyte activation 6 16.7 NLRC3, EOMES, BCL11B, CD8A, LCK, KLRK1 6.92E-05 0.014
Immune response 9 25.0 CXCL13, EOMES, CCL5, SNCA, RGS1, CD8A, CTLA4, GZMA, TRBC1 9.46E-05 0.014
T cell activation 5 13.9 NLRC3, EOMES, BCL11B, CD8A, LCK 1.63E-04 0.019
T cell differentiation 4 11.1 EOMES, BCL11B, CD8A, LCK 3.92E-04 0.038
doi:10.1371/journal.pone.0169894.t003
Table 4. Enriched Pathways among Differentially Expressed Genes in Incipient CLAD.
Category Term Count % Genes p-value adjusted
p-value
Reactome
Pathway
Signaling in Immune
system
6 16.7 CD8a molecule; T cell receptor beta variable 19; Killer cell lectin-like
receptor subfamily C, member 1; Killer cell lectin-like receptor subfamily D,
member 1; Killer cell lectin-like receptor subfamily K, member 1;
Lymphocyte-specific protein tyrosine kinase
2.3E-05 9.1E-05
KEGG
Pathway
Natural killer cell
mediated cytotoxicity
5 13.9 Killer cell lectin-like receptor subfamily C, member 1; Killer cell lectin-like
receptor subfamily D, member 1; Killer cell lectin-like receptor subfamily K,
member 1; Lymphocyte-specific protein tyrosine kinase; Perforin 1 (pore
forming protein);
1.3E-04 0.0028
KEGG
Pathway
Graft-versus-host
disease
3 8.3 Killer cell lectin-like receptor subfamily D, member 1; Killer cell lectin-like
receptor subfamily K, member 1; Perforin 1 (pore forming protein)
0.0030 0.033
KEGG
Pathway
Antigen processing and
presentation
3 8.3 CD8a molecule; Killer cell lectin-like receptor subfamily C, member 1; Killer
cell lectin-like receptor subfamily D, member 1
0.013 0.093
KEGG
Pathway
T cell receptor signaling
pathway
3 8.1 CD8a molecule; Cytotoxic T-lymphocyte-associated protein 4; Lymphocyte-
specific protein tyrosine kinase
0.022 0.11
doi:10.1371/journal.pone.0169894.t004
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[24, 25]. Furthermore, in rodent models, we and others have demonstrated that in vivo neu-
tralization of CCL5 significantly attenuates lung and airway allograft rejection [24]. We also
find that incipient CLAD is associated with the upregulated expression of CXCL13. CXCL13 is
most commonly known to recruit and control the organization of B cells within lymphoid fol-
licles [26]. However, CXCL13 expression is also induced in mature macrophages during
chronic inflammation and CXCL13 expression by lymphoid like stroma within the allograft
has been described in renal and cardiac transplant rejection, as well as with CLAD [27–29].
Fig 4. Principal component analysis. Principal component analysis based on the 40 differentially expressed candidate genes demonstrates modest
separation of incipient CLAD and CLAD free groups. The percentage of total variance accounted for by the first principal component was 63.2%, and
for the second principal component was 15.1%.
doi:10.1371/journal.pone.0169894.g004
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In addition to genes related to the recruitment and retention of mononuclear immune cells
in incipient CLAD samples, we also find differential gene expression related to activation and
proliferation of these cells. In particular, prior to the development of CLAD we find differential
expression of genes related to activation and proliferation of cytotoxic lymphocytes (CD8+
T-cells and NK cells). For instance, we find increased expression of both CD8a and LCK
proto-oncogene, Src family tyrosine kinase (LCK). CD8 acts to stabilize binding of the T-cell
receptor (TCR) to the peptide-MHC complex, while also localizing LCK to the TCR/CD3
complex to facilitate early signaling events during T-cell activation [30]. Furthermore,
Fig 5. Hierarchical clustering and heat map. Hierarchical clustering and heat map based on the expression index of n = 40 candidate genes.
doi:10.1371/journal.pone.0169894.g005
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incipient CLAD was associated with upregulated expression of genes in the NKG2 family of
receptors (killer cell lectin like receptor [KLR] C1, KLRD1, KLRK1), which are expressed by
both NK and CD8+ cells and provide activating or costimulatory signals [31]. Similarly,
KLRB1 was upregulated in incipient CLAD samples, which is primarily thought to mediate
NK cell function [32]. We also find increased expression of transcripts encoding key regulators
of cytotoxic cells including regulator of G Protein Signaling-1 (RGS1), eomesodermin
(EOMES), B-cell CLL/lymphoma 11B (zinc finger protein), synuclein, alpha (SNCA), and T
cell receptor beta constant 1 (TRBC1), all of which are involved in different aspects of differen-
tiation and proliferation/clonal expansion of effector memory cells [33–37]. Finally, both
CD8+ T cells and NK cells have conserved pathways that mediate target allograft cell injury via
perforin, granzymes and granulysin, each of which is differentially over-expressed in incipient
CLAD cases [38].
It is also of interest that multiple genes related to hemoglobin (HB) expression are increased
in the BAL CP from cases of incipient CLAD. Although RBC’s lack a nucleus, a microarray
study of human RBC’s demonstrated the presence of transcripts for 1019 genes in human
RBCs including genes for hemoglobin [39]. Therefore, we have interpreted the evidence of
hemoglobin transcripts in the BAL CP as evidence for RBC’s in the BAL CP. Taken in the con-
text with simultaneous upregulated signals for potentially injurious CD8+ T cells and NK cells,
this suggests a subclinical lung allograft injury with micro-hemorrhage. Importantly, we have
also found that incipient CLAD CPs have a distinct downregulation of fibronectin type III
domain containing 3B (FNDC3B), which is considered a putative marker of stem/progenitor
cells [40]. This derangement may indicate an inability for allograft lung to repair and reverse
remodel allowing for structural damage and CLAD.
Functional annotation analyses of our list of differentially expressed genes in incipient
CLAD samples led to similar conclusions. Enriched GO terms suggest activation and differen-
tiation of mononuclear immune cells. Similarly, our gene list was significantly enriched for
several biologic pathways, each related to either innate or adaptive immunity. Taken together,
these findings indicate that the pathogenesis of CLAD involves immune activation that would
be expected with a rejection process, and that these biologic derangements are evident in the
BAL CP prior to our ability to make a clinical diagnosis of CLAD.
In fact, our study suggests that the performance of the BAL CP transcriptome as a bio-
marker for predicting CLAD risk may be quite good. Hierarchical cluster analyses correctly
grouped the majority of incipient CLAD and CLAD free samples. In these analyses, one incipi-
ent CLAD sample (#1072) was misclassified with CLAD free samples. In this case, the CLAD
diagnosis occurred 167 days after sampling, concurrent with a subtherapeutic tacrolimus
trough, after previous levels were consistently within or above the target range. Two CLAD
free samples (#1780 and #2029) were misclassified with incipient CLAD samples. These
patients remained CLAD free at the end of follow-up 1399 and 1568 days after the respective
sample dates. The first subject (#1780) had previously experienced refractory AR, which was
treated with basiliximab and IVIG, with resolution of AR by the time of the study sample.
Thereafter, the patient’s immune suppressive regimen was changed from Tacrolimus/MMF/
prednisone to Tacrolimus/Rapamycin/prednisone due to concern about elevated risk of
CLAD. The second subject (#2029) experienced a 12% decline in FEV1 shortly after the study
sample. Azithromycin immunomodulation (250 mg M,W,F) was added to the patient’s
immune suppression regimen. It is not possible to know whether the changes in management
impacted the allograft immunobiology and CLAD outcomes in these 2 patients.
Our study is the first to examine BAL CP gene expression patterns relative to CLAD patho-
genesis. However, there are strikingly common themes in several previous studies of gene
expression in the lung during biopsy proven AR. Two such studies have examined BAL CP
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gene expression during AR and concluded that the BAL CP is a reliable source of RNA for
transcriptome analysis [41, 42]. Similar to our findings with incipient CLAD, AR was associ-
ated with differential expression of granzyme, perforin, CD8, cytotoxic T-lymphocyte-
associated protein 4 (CTLA-4), and T-cell receptor genes. Our group has also recently pub-
lished RNA-Seq gene expression profiles from BAL fluid exosomes in lung transplant recipi-
ents with AR, and contrasted exosomal profiles with the CP from the same BAL sample [43].
In that study, the AR BAL CP expression profiles again exhibit similarities to incipient CLAD
samples. Specific genes we find upregulated from both AR and incipient CLAD CPs included
CXCL13, CTLA-4, and KLRC1 [43]. Given the similarities in gene expression, it is possible
that incipient CLAD is synonymous with undiagnosed AR, and CLAD may represent the con-
sequence of untreated subclinical AR. Previous studies suggest that even a single episode of
minimal AR places the patient at increased risk for CLAD [44, 45]. Although transbronchial
biopsy is the current “gold standard” for AR diagnosis, the sampling error and the interob-
server variability of biopsy interpretation are well documented [42, 46–49]. Furthermore,
transbronchial biopsy is invasive and associated with risks of bleeding, pneumothorax, and
respiratory failure. Therefore, the lower risk and larger area of lung sampled by BAL, as well as
the lack of subjectivity involved with gene expression analysis, may be advantages over trans-
bronchial biopsy for monitoring allograft status. As acute cellular rejection is defined based on
alveolar infiltration while CLAD (BOS phenotype) is airway centric, perhaps CLAD and AR
both represent allorecognition manifest as a specific T cell signature, and that perhaps CLAD
and AR differ in target antigen and compartment (bronchiole in CLAD vs alveolus in AR). If
future studies confirm gene expression similarities between AR and incipient CLAD, then per-
haps augmented immune suppression could prevent progression to CLAD in these at-risk
patients. The prospect of a better, safer test to guide therapies which may prevent CLAD could
have enormous implications on the lung transplant field. However, given our small sample
size and lack of a controlled intervention, these findings require confirmation in a larger multi-
center study, followed by an interventional clinical trial, before they can impact our practice.
In addition to our small sample size, other factors in this study warrant caution in interpret-
ing our findings. We defined CLAD as a 20% decline in FEV1 from baseline and excluded
samples collected after CLAD. “Potential CLAD”, which can be defined as a 10% decline in
FEV1 from baseline, was not considered CLAD. All 5 patients with “potential CLAD” ended
up in the incipient CLAD group. We explored repeating the analyses after exclusion of patients
in the potential-CLAD group and our major findings and interpretations were not affected
(data not shown). The very specific selection criteria for samples used in this study may limit
the generalizability of our findings. Our incipient CLAD cases went on to develop CLAD
within 2 years of sampling. Our CLAD free controls were patients who remained CLAD free
for the duration of follow-up and for at least 4 years following the BALF sample. Patients who
develop CLAD within 2–4 years were excluded from this study and it is unknown what expres-
sion profile this group would exhibit. We also excluded patient samples with either concurrent
infection or AR. While this allowed for the focused analyses of the differentially expressed
genes associated with incipient CLAD, the application of these methods in the clinic would be
complicated by these relatively common occurrences in patients. The design of future studies
would benefit from a larger sample size and inclusion of a more representative group of
specimens.
In summary, we showed that the BAL CP transcriptome in incipient CLAD cases was indic-
ative of activated innate and adaptive cytotoxic immune responses. These findings indicate
that a pathobiology, similar to AR, precedes a clinical diagnosis of CLAD. Both hierarchical
clustering and a supervised machine learning tool were able to correctly categorize most sam-
ples into incipient CLAD and CLAD-free categories, suggesting potential prognostic utility. A
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larger prospective investigation of BAL CP transcriptome as a biomarker for CLAD risk strati-
fication is warranted.
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